Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Suga

Showing results (271-280 of 273) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 273 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2023
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trialK Jhaveri, L D Eli, H Wildiers, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|August 19, 2008
The first nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy. Part 1: a general view of antibacterial susceptibilityY Niki, H Hanaki, M Yagisawa, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|June 26, 2009
Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens' antibacterial susceptibilityY Niki, H Hanaki, T Matsumoto, et al.
Pageof 28

Showing results (271-280 of 273) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 273 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2023
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trialK Jhaveri, L D Eli, H Wildiers, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|August 19, 2008
The first nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy. Part 1: a general view of antibacterial susceptibilityY Niki, H Hanaki, M Yagisawa, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|June 26, 2009
Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens' antibacterial susceptibilityY Niki, H Hanaki, T Matsumoto, et al.
Pageof 28